Intrinsiqq
Molecular Partners AG ADR logo

Molecular Partners AG ADR Financials

MOLN

Compare

All currency values in CHF millions unless otherwise noted

Scroll

Income Statement
TTM
DEC 2025
DEC 2024
DEC 2023
DEC 2022
DEC 2021
Revenues
RevenueCHF 0CHF 0CHF 5CHF 7CHF 190CHF 9
Operating Income-CHF 52-CHF 55-CHF 61-CHF 61CHF 117-CHF 63
Non-Operating
Net Interest Expense-CHF 0-CHF 0-CHF 0-CHF 0-CHF 1-CHF 1
Income Tax ExpenseCHF 0CHF 0CHF 0CHF 0CHF 0CHF 0
Net Income
Net Income-CHF 51-CHF 62-CHF 54-CHF 62CHF 118-CHF 64
Per Share Data
Revenue Per ShareCHF 0.00CHF 0.00CHF 0.15CHF 0.24CHF 6.48CHF 0.33
EPS (Basic)-CHF 1.37-CHF 1.65-CHF 1.59-CHF 1.89CHF 3.63-CHF 2.06
EPS (Diluted)-CHF 1.37-CHF 1.65-CHF 1.59-CHF 1.89CHF 3.54-CHF 2.06
Shares Outstanding38.3M37.3M34.0M28.8M29.3M27.9M

Molecular Partners AG ADR (MOLN) financials: revenue, profit and margins

Molecular Partners AG ADR (MOLN) generated about CHF 0.00 in revenue and -CHF 51 million in net income over the trailing twelve months, growing at roughly -18.9% a year. Figures are from company filings; this is analysis, not investment advice.

Frequently asked

What is Molecular Partners AG ADR's (MOLN) revenue?+

Molecular Partners AG ADR generated about CHF 0.00 in revenue over the trailing twelve months. Revenue has grown at roughly -18.9% a year over the past five years. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.

Is Molecular Partners AG ADR profitable?+

Molecular Partners AG ADR reported about -CHF 51 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.

How fast is Molecular Partners AG ADR growing?+

Molecular Partners AG ADR's revenue has compounded at roughly -18.9% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside MOLN's margins and free cash flow. This is analysis from company filings, not investment advice.

How the market compares: How many US companies are profitable

Peers

Biotechnology · Pick stocks to compare with MOLN

CompareIntrinsic value
NEWBRY.XSTONewbury Pharmaceuticals AB
€0.11+0.91%40
HPHA.XETRHeidelberg Pharma AG
€2.01-2.90%10
MEDCL.XPARMedincell SA
€26.70-2.05%40
ZTEKZentek Ltd.
€0.33-0.60%40
XTXXFAdastra Holdings Ltd.
€0.08+0.00%40
XRTXXORTX Therapeutics Inc.
$0.84-5.73%10
VALNValneva SE Sponsored ADR
$5.16-3.82%0
TRIBTrinity Biotech plc Sponsored ADR
$6.24+13.66%10

Spot a number that looks wrong?

Download this analysis as a PDF (Pro)

Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing MOLN

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.